Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series.

Lockhart A, Kirby B, McGuigan C.

Mult Scler Relat Disord. 2019 Oct;35:239-240. doi: 10.1016/j.msard.2019.08.008. Epub 2019 Aug 5.

PMID:
31421627
2.

Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.

Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y.

Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16.

PMID:
31369274
3.

Prevalence and Risk Factors of Trichomonas vaginalis Among Female Sexual Workers in Nairobi, Kenya.

Lockhart A, Senkomago V, Ting J, Chitwa M, Kimani J, Gakure H, Kwatampora J, Patel S, Mugo N, Smith JS.

Sex Transm Dis. 2019 Jul;46(7):458-464. doi: 10.1097/OLQ.0000000000001002.

PMID:
31194717
4.

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC.

J Gastrointest Oncol. 2019 Jun;10(3):412-420. doi: 10.21037/jgo.2019.02.01.

5.

Compartmentalized gut lymph node drainage dictates adaptive immune responses.

Esterházy D, Canesso MCC, Mesin L, Muller PA, de Castro TBR, Lockhart A, ElJalby M, Faria AMC, Mucida D.

Nature. 2019 May;569(7754):126-130. doi: 10.1038/s41586-019-1125-3. Epub 2019 Apr 15.

6.

Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.

Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K.

J Clin Pharmacol. 2019 Sep;59(9):1204-1215. doi: 10.1002/jcph.1416. Epub 2019 Apr 15.

PMID:
30985952
7.

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.

Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ.

Int J Cancer. 2019 Nov 1;145(9):2450-2458. doi: 10.1002/ijc.32317. Epub 2019 Jun 14.

8.

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.

Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26.

PMID:
30915497
9.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol. 2019 Jul;85(7):1464-1473. doi: 10.1111/bcp.13915. Epub 2019 May 17.

10.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
11.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K.

JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441.

PMID:
30570649
12.

Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG.

J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617.

PMID:
30371873
13.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]

14.

Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, Lewis KB, Ecsedy J, Washington K, Beauchamp RD, El-Rifai W.

Gastroenterology. 2019 Feb;156(3):662-675.e7. doi: 10.1053/j.gastro.2018.10.030. Epub 2018 Oct 17.

PMID:
30342037
15.

What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?

De Mello RA, Castelo-Branco L, Castelo-Branco P, Pozza DH, Vermeulen L, Palacio S, Salzberg M, Lockhart AC.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:249-261. doi: 10.1200/EDBK_198805. Review.

PMID:
30231398
16.

Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.

Samson P, Puri V, Lockhart AC, Robinson C, Broderick S, Patterson GA, Meyers B, Crabtree T.

J Thorac Cardiovasc Surg. 2018 Oct;156(4):1725-1735. doi: 10.1016/j.jtcvs.2018.05.100. Epub 2018 Jun 28.

PMID:
30054137
17.

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH.

Cancer Res. 2018 Sep 15;78(18):5398-5407. doi: 10.1158/0008-5472.CAN-18-0316. Epub 2018 Jul 24.

18.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

19.

Small vessels, dementia and chronic diseases - molecular mechanisms and pathophysiology.

Horsburgh K, Wardlaw JM, van Agtmael T, Allan SM, Ashford MLJ, Bath PM, Brown R, Berwick J, Cader MZ, Carare RO, Davis JB, Duncombe J, Farr TD, Fowler JH, Goense J, Granata A, Hall CN, Hainsworth AH, Harvey A, Hawkes CA, Joutel A, Kalaria RN, Kehoe PG, Lawrence CB, Lockhart A, Love S, Macleod MR, Macrae IM, Markus HS, McCabe C, McColl BW, Meakin PJ, Miller A, Nedergaard M, O'Sullivan M, Quinn TJ, Rajani R, Saksida LM, Smith C, Smith KJ, Touyz RM, Trueman RC, Wang T, Williams A, Williams SCR, Work LM.

Clin Sci (Lond). 2018 Apr 30;132(8):851-868. doi: 10.1042/CS20171620. Print 2018 Apr 30.

20.

New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.

McNicholas N, Lockhart A, Yap SM, O'Connell K, Tubridy N, Hutchinson M, McGuigan C.

Mult Scler. 2019 May;25(6):867-870. doi: 10.1177/1352458518770088. Epub 2018 Apr 12.

PMID:
29648501
21.

Prospective Evaluation of Cervicovaginal Self- and Cervical Physician Collection for the Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium Infections.

Lockhart A, Psioda M, Ting J, Campbell S, Mugo N, Kwatampora J, Chitwa M, Kimani J, Gakure A, Smith JS.

Sex Transm Dis. 2018 Jul;45(7):488-493. doi: 10.1097/OLQ.0000000000000778.

PMID:
29465667
22.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12.

23.

Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).

Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassiv SD, Montero AJ, Schefter TE.

Ann Oncol. 2019 Feb 1;30(2):345. doi: 10.1093/annonc/mdx813. No abstract available.

24.

A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers.

Zhu S, Chen Z, Wang L, Peng D, Belkhiri A, Lockhart AC, El-Rifai W.

Clin Cancer Res. 2018 Apr 15;24(8):1905-1916. doi: 10.1158/1078-0432.CCR-17-1716. Epub 2018 Jan 31.

25.

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH.

J Neurooncol. 2018 May;138(1):105-111. doi: 10.1007/s11060-018-2775-y. Epub 2018 Jan 27.

PMID:
29374809
26.

Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer.

Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC.

J Gastrointest Oncol. 2017 Dec;8(6):985-989. doi: 10.21037/jgo.2017.08.16.

27.

The Smc5/6 complex regulates the yeast Mph1 helicase at RNA-DNA hybrid-mediated DNA damage.

Lafuente-Barquero J, Luke-Glaser S, Graf M, Silva S, Gómez-González B, Lockhart A, Lisby M, Aguilera A, Luke B.

PLoS Genet. 2017 Dec 27;13(12):e1007136. doi: 10.1371/journal.pgen.1007136. eCollection 2017 Dec.

28.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029. Erratum in: JAMA Oncol. 2019 Jan 1;5(1):122.

29.

Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.

Vlacich G, Samson PP, Perkins SM, Roach MC, Parikh PJ, Bradley JD, Lockhart AC, Puri V, Meyers BF, Kozower B, Robinson CG.

Cancer Med. 2017 Dec;6(12):2886-2896. doi: 10.1002/cam4.1250. Epub 2017 Nov 15.

30.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC.

Cell. 2017 Aug 10;170(4):637-648.e10. doi: 10.1016/j.cell.2017.06.048. Epub 2017 Jul 27.

31.

Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.

Samson P, Lockhart AC.

J Gastrointest Oncol. 2017 Jun;8(3):418-429. doi: 10.21037/jgo.2016.11.13. Review.

32.

Telomere Length Determines TERRA and R-Loop Regulation through the Cell Cycle.

Graf M, Bonetti D, Lockhart A, Serhal K, Kellner V, Maicher A, Jolivet P, Teixeira MT, Luke B.

Cell. 2017 Jun 29;170(1):72-85.e14. doi: 10.1016/j.cell.2017.06.006.

33.

Exploiting a host-commensal interaction to promote intestinal barrier function and enteric pathogen tolerance.

Pedicord VA, Lockhart AAK, Rangan KJ, Craig JW, Loschko J, Rogoz A, Hang HC, Mucida D.

Sci Immunol. 2016 Sep;1(3). pii: eaai7732. doi: 10.1126/sciimmunol.aai7732. Epub 2016 Sep 22.

34.

Opportunities and Challenges of Adolescent and Adult Vaccination Administration Within Pharmacies in the United States.

Islam JY, Gruber JF, Lockhart A, Kunwar M, Wilson S, Smith SB, Brewer NT, Smith JS.

Biomed Inform Insights. 2017 Feb 16;9:1178222617692538. doi: 10.1177/1178222617692538. eCollection 2017. Review.

35.

Mechanisms of vascular disease in dementia: what does industry want to know?

Wren PB, Hill D, Lockhart A.

Clin Sci (Lond). 2017 May 1;131(9):799-802. doi: 10.1042/CS20160724.

PMID:
28424374
36.

Genetics of Gastric Cancer.

Strand MS, Lockhart AC, Fields RC.

Surg Clin North Am. 2017 Apr;97(2):345-370. doi: 10.1016/j.suc.2016.11.009. Review.

PMID:
28325191
37.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

38.

Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis.

Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, Shafiq F, Kotol PF, Bouslimani A, Melnik AV, Latif H, Kim JN, Lockhart A, Artis K, David G, Taylor P, Streib J, Dorrestein PC, Grier A, Gill SR, Zengler K, Hata TR, Leung DY, Gallo RL.

Sci Transl Med. 2017 Feb 22;9(378). pii: eaah4680. doi: 10.1126/scitranslmed.aah4680.

39.

Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.

Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, McKinney DA, Brown M, Poole C, Willame C, Smith JS.

Int J Cancer. 2017 Jul 1;141(1):8-23. doi: 10.1002/ijc.30623. Epub 2017 Feb 27. Review.

40.

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.

Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O.

Cancer Chemother Pharmacol. 2017 Feb;79(2):339-351. doi: 10.1007/s00280-016-3210-8. Epub 2017 Jan 5.

41.

Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcusaureus and Encoded Virulence Factors.

Merriman JA, Mueller EA, Cahill MP, Beck LA, Paller AS, Hanifin JM, Ong PY, Schneider L, Babineau DC, David G, Lockhart A, Artis K, Leung DY, Schlievert PM.

mSphere. 2016 Dec 7;1(6). pii: e00295-16. eCollection 2016 Nov-Dec.

42.

Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.

Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, Piechocka-Trocha A, Walker BD, Chibnik LB, Jost S, Porichis F.

J Int AIDS Soc. 2016 Dec 9;19(1):21136. doi: 10.7448/IAS.19.1.21136. eCollection 2016.

43.

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.

Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S.

Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927. Epub 2016 Sep 28.

PMID:
27681579
44.

Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.

Kelly KR, Gabrail N, Weitman S, Sarantopoulos J, Olszanski AJ, Edenfield W, Venitz J, Reddy G, Yang A, Hasal SJ, Lockhart AC.

Cancer Chemother Pharmacol. 2016 Nov;78(5):929-939. Epub 2016 Sep 16.

PMID:
27638045
45.

Noncolorectal Gastrointestinal Cancers-What Did We Learn in 2016?

Du L, Lockhart AC.

JAMA Oncol. 2017 Feb 1;3(2):157-158. doi: 10.1001/jamaoncol.2016.3728. No abstract available.

PMID:
27768170
46.
47.

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH.

Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4.

48.

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H.

J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312.

PMID:
27697982
49.

Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.

Samson P, Robinson C, Bradley J, Lockhart AC, Puri V, Broderick S, Kreisel D, Krupnick AS, Patterson GA, Meyers B, Crabtree T.

J Thorac Oncol. 2016 Dec;11(12):2227-2237. doi: 10.1016/j.jtho.2016.07.031. Epub 2016 Aug 17.

50.

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects.

Huiban M, Coello C, Wu K, Xu Y, Lewis Y, Brown AP, Buraglio M, Guan C, Shabbir S, Fong R, Passchier J, Rabiner EA, Lockhart A.

Mol Imaging Biol. 2017 Feb;19(1):153-161. doi: 10.1007/s11307-016-0982-5.

Supplemental Content

Loading ...
Support Center